October 29, 2023
3 min watch
Save
VIDEO: Interim results promising for RGX-314 in diabetic retinopathy
SEATTLE — In this Healio Video Perspective from the ASRS meeting, Dilsher Dhoot, MD, discusses the interim results of the phase 2 ALTITUDE trial investigating three doses of RGX-314 gene therapy in diabetic retinopathy.
“If we look at dose levels one and two, we saw ‘any improvement’ in [Diabetic Retinopathy Severity Scale] of 54% in both doses combined compared to 20% improvement in the sham group,” he said.
Dhoot also discussed 6-month safety data.
Published by:
Sources/Disclosures
Collapse
Source:
Dhoot D. Suprachoroidal delivery of RGX-314 gene therapy for diabetic retinopathy: The phase II ALTITUDE study. Presented at: American Society of Retina Specialists annual meeting; July 28-Aug. 1, 2023; Seattle.
Disclosures:
Dhoot reports being a consultant for and an investor in Regenxbio.
Read more about